AU2001249182A1 - Use of rapamycin and agents that inhibit b7 activity in immunomodulation - Google Patents

Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Info

Publication number
AU2001249182A1
AU2001249182A1 AU2001249182A AU4918201A AU2001249182A1 AU 2001249182 A1 AU2001249182 A1 AU 2001249182A1 AU 2001249182 A AU2001249182 A AU 2001249182A AU 4918201 A AU4918201 A AU 4918201A AU 2001249182 A1 AU2001249182 A1 AU 2001249182A1
Authority
AU
Australia
Prior art keywords
immunomodulation
rapamycin
inhibit
agents
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249182A
Inventor
Mark J. Collins
Joseph Sypek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of AU2001249182A1 publication Critical patent/AU2001249182A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001249182A 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation Abandoned AU2001249182A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18910600P 2000-03-14 2000-03-14
US60189106 2000-03-14
PCT/US2001/008016 WO2001068133A1 (en) 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Publications (1)

Publication Number Publication Date
AU2001249182A1 true AU2001249182A1 (en) 2001-09-24

Family

ID=22695958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249182A Abandoned AU2001249182A1 (en) 2000-03-14 2001-03-13 Use of rapamycin and agents that inhibit b7 activity in immunomodulation

Country Status (3)

Country Link
US (2) US20010055593A1 (en)
AU (1) AU2001249182A1 (en)
WO (1) WO2001068133A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20070148162A1 (en) * 2003-02-27 2007-06-28 Ranjit Bhardwaj Molecule which binds cd80 and cd86
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
EA201592106A3 (en) 2013-05-03 2016-08-31 Селекта Байосайенсиз, Инк. LOCAL ACCOMPANYING INTRODUCTION OF TOLEROGENOUS SYNTHETIC NANOSATORS TO REDUCE HYPERSENSITIVITY TYPE I AND HYPERSENSITIVITY TYPE IV
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
BR112019018748A2 (en) 2017-03-11 2020-04-07 Selecta Biosciences Inc methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120727A (en) * 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5202332A (en) * 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
ES2148224T3 (en) * 1992-03-30 2000-10-16 American Home Prod RAPAMICINE FORMULATION FOR INTRAVENOUS INJECTIONS.
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
HUP0000833A3 (en) * 1997-01-10 2001-09-28 Biogen Idec Ma Inc Cambridge Treatment of lupus nephritis with anti-cd40l compounds
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
AU735592B2 (en) * 1997-05-17 2001-07-12 Biogen Idec Ma Inc. Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
WO1998058965A2 (en) * 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
WO1999045009A1 (en) * 1998-03-04 1999-09-10 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
PL350909A1 (en) * 1999-02-12 2003-02-10 Genetics Inst Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ATE353365T1 (en) * 1999-08-23 2007-02-15 Dana Farber Cancer Inst Inc NEW B7-4 MOLECULES AND THEIR USES

Also Published As

Publication number Publication date
US20070092506A1 (en) 2007-04-26
US20010055593A1 (en) 2001-12-27
WO2001068133A1 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
AU2609901A (en) Antimicrobial compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
IL148657A0 (en) Stent range transducers and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU1387400A (en) Verification of software agents and agent activities
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001273074A1 (en) Combinations of ssri and estrogenic agents
AU2001233951A1 (en) Improvements in and relating to active noise reduction
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
AU1164601A (en) Therapeutic use and formulation
AU4848200A (en) Intravascular device and methods of manufacture and use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU8037900A (en) Modular processing devices and methods of use
AU2001249182A1 (en) Use of rapamycin and agents that inhibit b7 activity in immunomodulation
AU3732500A (en) Beclin and uses thereof
AU2001275036A1 (en) Protected forms of a combination of pharmacologically active agents and uses therefor
AU2001261375A1 (en) Human caspase-12 materials and methods
AU3501700A (en) Human endokine alpha and methods of use
AU6519198A (en) Melaninization inhibitor, skin-care preparation, and bath agent
AU2001259441A1 (en) Cellular regulators of infectious agents and methods of use
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001268236A1 (en) Use of aicar and related compounds
AU6102899A (en) Production and use of antimicrobial agents
AU2529501A (en) Macrocyclic compounds and their use